重组抗人CD19单抗(4G7)流式 | Syd Labs PA007511.m1
重组抗人CD19单克隆抗体(克隆号4G7) ，小鼠IgG1 Kappa(Syd Labs货号：PA007511.m1)是用哺乳动物细胞生产的重组抗体，可用于流式细胞术和免疫组织化学-冷冻等研究，纯度>95%。其不变区为小鼠Mouse IgG1 Kappa (mIgG1或m1)，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007511.m1 |
|---|---|
| 产品名称 | 重组抗人CD19单抗(4G7)流式 | Syd Labs PA007511.m1 |
| 英文名 | Recombinant Anti-human CD19 Monoclonal Antibody (Clone: 4G7), Mouse IgG1 Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | B 淋巴细胞抗原 CD19，分化簇 19，B 淋巴细胞表面抗原 B4，T 细胞表面抗原 Leu-12，CVID3 |
| 概述 | Syd Labs提供重组小鼠IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 4G7 |
| 同种型 | 小鼠 IgG1 kappa |
| 特异性 | 该重组 4G7 抗体与人 CD19 蛋白特异性结合 |
| 免疫源 | 重组抗人CD19单克隆抗体 (克隆：4G7)在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，含0.09%叠氮化钠 |
| 偶联 | 非偶联 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 重组抗人CD19单克隆抗体(克隆号4G7) ，小鼠IgG1 Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 12个月，保存在2 至 8°C。 请勿冻结。 |
| 注意事项 | PA007511.m1 Syd Labs提供重组小鼠IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | 流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）。 |
文献
重组抗人CD19单克隆抗体(克隆号4G7) ，小鼠IgG1 Kappa（Recombinant Anti-human CD19 Monoclonal Antibody (Clone: 4G7), Mouse IgG1 Kappa，货号：PA007511.m1 Syd Labs）
4G7抗体可结合人CD19蛋白，该蛋白是一种表达于包括人浆细胞在内的所有B系细胞表面的跨膜蛋白。CD19在人B细胞中发挥两大核心作用：一是作为接头蛋白将细胞质信号蛋白招募至细胞膜，二是在CD19/CD21复合物中发挥作用，以降低B细胞受体信号通路的激活阈值。CD19是B淋巴细胞发育及淋巴瘤诊断的重要生物标志物，同时也可用作白血病免疫治疗的靶点。
抗人CD19单抗(4G7)参部分考文献:
1.Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma
Lownik, J., et al. Clin Cancer Res. 2024 Jul 15;30(14):2895-2904. PMID: 38661647
“Epitope mapping of the CD19 extracellular domain revealed that the antigen-recognition domains of CAR-T cells (based on FMC63 antibody) and tafasitamab (based on 4G7 antibody) have partially overlapping, conformationally sensitive epitopes dependent on spatially adjacent loops coded by exons 3 and 4. Splice variations in exon 2 could lead to epitope loss for both therapies. The study emphasizes the need for prospective studies to correlate pretreatment and posttreatment CD19 expression with clinical responses to optimize sequencing of CD19-directed immunotherapies for diffuse large B-cell lymphoma (DLBCL).”
2.IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
Hörner, S., et al. Cancers (Basel). 2022 Aug 16;14(16):3941. PMID: 36010934
“The study utilized codon-optimized variable domains of humanized Apo-1, 2H7, 4G7 (anti-human CD19), and MOPC-21 antibodies for transfection into CHO cells. Bispecific antibodies combined the CD95 agonist Apo-1 with either anti-CD20 (clone 2H7) or anti-CD19 (clone 4G7) in F(ab)2 and single-chain formats. The CD19 binding affinity showed an EC50 of approximately 7.5 nM, despite 4G7’s higher affinity compared to 2H7. Flow cytometry revealed CD20 expression was 3–10-fold higher than CD19, with Raji cells expressing over 20,000 CD19 and 190,000 CD20 molecules per cell.”
3.Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody
Seidel, U. J., et al. Mol Ther. 2016 Sep 6;24(9):1634-43. PMID: 27380762
“The Fc-optimized CD19 antibody 4G7SDIE, a humanized version of the murine 4G7 antibody (anti-human CD19) with S239D and I332E modifications, was tested in B-lineage ALL blasts from 18 patients and 5 4G7SDIE-treated patients. The antibody was detected via indirect immunofluorescence staining and flow cytometry. 4G7SDIE enhanced antibody-dependent cellular cytotoxicity (ADCC) against leukemic blasts, showing promise for minimal residual disease (MRD) treatment due to favorable target-to-effector cell ratios.”
4.Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells
Kellner, C., et al. Cancer Lett. 2011 Jul 28;306(1):88-95. PMID: 21339041
“The study utilized the 4G7 hybridoma (anti-human CD19; IgG1) and 3G8 (CD16; IgG1) to create Fab–scFv fusion proteins combining CD19-directed Fab fragments with CD19 and CD16 scFvs. CD19, a 95 kDa transmembrane glycoprotein, is a promising target for B-cell malignancy treatments due to its favorable properties. The bispecific antibodies demonstrated effective antibody-dependent cellular cytotoxicity (ADCC) against B-lymphoid tumor cells, highlighting CD19’s potential in immunotherapy.”
5.Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
Horton, H. M., et al. Cancer Res. 2008 Oct 1;68(19):8049-57. PMID: 18829563
“The study developed XmAb5574, a humanized and affinity-matured version of the mouse anti-CD19 antibody 4G7 with S239D/I332E Fc modifications. XmAb5574 and other anti-CD19 antibodies showed approximately 2-fold higher binding affinity than 4G7. In vitro, target cells opsonized with antibodies were mixed with NK cells, and LDH release was measured. In vivo, fluorescence-activated cell sorting confirmed CD19 expression and tumor cell percentages, demonstrating potent activity against lymphoma and leukemia.”